Marcel Menon Miyake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcel Menon Miyake has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin S. Bleier
Department of Otolaryngology‐Head and Neck Surgery, Mass Eye and Ear Harvard Medical School Boston Massachusetts USA
6 shared publications Benjamin S. Bleier
Massachusetts Eye and Ear Infirmary, Department of Otolaryngology-Head and Neck Surgery, Boston, United States; Harvard Medical School, Department of Otology and Laryngology, Boston, United States
4 shared publications- Wilma Terezinha Anselmo Lima
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
4 shared publications - Edwin Tamashiro
Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto (FMRP), Ribeirão Preto, SP, Brazil
3 shared publications - Fabiana Cardoso Pereira Valera
Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
3 shared publications - Marco Aurélio Fornazieri
Universidade Estadual de Londrina (UEL), Departamento de Cirurgia Clínica, Londrina, PR, Brazil
3 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (7) , 681-688
Effect of Budesonide Nasal Irrigation in Patients With Chronic Rhinosinusitis With Nasal Polyps Without Prior Sinus Surgery: A Randomized, Double‐Blind, Placebo‐Controlled Study
Background: The indication for nasal irrigation with corticosteroids after sinus surgery in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is well established, as surgery facilitates distribution throughout the sinonasal cavity. However, it remains unknown whether this approach could also provide therapeutic benefit prior to surgery. This study aims to compare the effect of budesonide versus saline nasal irrigation in surgically naive CRSwNP patients. Methods: A randomized, double‐blind, placebo‐controlled parallel‐group study was conducted in 52 patients with diffuse type 2 CRSwNP with no previous sinus surgery. Patients were randomized to receive either 1 mg budesonide or saline nasal irrigation twice daily for four weeks. The primary outcome was the change in the 22‐item Sinonasal Outcome Test (SNOT‐22). Secondary outcomes included the Visual Analogue Scale (VAS), Nasal Polyp Score (NPS), and the Connecticut (CCCRC) olfactory test. Results: A total of 52 patients were randomized (mean age 50.1 ± 12.9 years; 51.9% female). The intention‐to‐treat (ITT) analysis showed that the budesonide nasal irrigation group demonstrated a significantly greater improvement in SNOT‐22 (mean difference: 18.1 points [95% CI: 3.4 to 32.8; p = 0.017]), VAS (mean difference 2.24 points [95% CI: 0.35 to 4.13; p = 0.018]) and NPS (mean difference: 0.73 points [95% CI: 0.25 to 1.21]; p = 0.003). No significant differences were observed between groups in CCCRC. Conclusion: Budesonide nasal irrigation may be an important tool for controlling sinonasal symptoms in patients with CRSwNP who are not candidates for sinus surgery or while awaiting surgical treatment.
- 13 February 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (7) , 681-688
Open AccessEffect of Budesonide Nasal Irrigation in Patients With Chronic Rhinosinusitis With Nasal Polyps Without Prior Sinus Surgery: A Randomized, Double‐Blind, Placebo‐Controlled Study
Background: The indication for nasal irrigation with corticosteroids after sinus surgery in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is well established, as surgery facilitates distribution throughout the sinonasal cavity. However, it remains unknown whether this approach could also provide therapeutic benefit prior to surgery. This study aims to compare the effect of budesonide versus saline nasal irrigation in surgically naive CRSwNP patients. Methods: A randomized, double‐blind, placebo‐controlled parallel‐group study was conducted in 52 patients with diffuse type 2 CRSwNP with no previous sinus surgery. Patients were randomized to receive either 1 mg budesonide or saline nasal irrigation twice daily for four weeks. The primary outcome was the change in the 22‐item Sinonasal Outcome Test (SNOT‐22). Secondary outcomes included the Visual Analogue Scale (VAS), Nasal Polyp Score (NPS), and the Connecticut (CCCRC) olfactory test. Results: A total of 52 patients were randomized (mean age 50.1 ± 12.9 years; 51.9% female). The intention‐to‐treat (ITT) analysis showed that the budesonide nasal irrigation group demonstrated a significantly greater improvement in SNOT‐22 (mean difference: 18.1 points [95% CI: 3.4 to 32.8; p = 0.017]), VAS (mean difference 2.24 points [95% CI: 0.35 to 4.13; p = 0.018]) and NPS (mean difference: 0.73 points [95% CI: 0.25 to 1.21]; p = 0.003). No significant differences were observed between groups in CCCRC. Conclusion: Budesonide nasal irrigation may be an important tool for controlling sinonasal symptoms in patients with CRSwNP who are not candidates for sinus surgery or while awaiting surgical treatment.
- 1 September 2023
- Published by Stichting Nase in Rhinology journal
- Vol. 62 (1) , 55-62
Smell loss associated with SARS-CoV-2 is not clinically different from other viruses: a multicenter cohort study
Background: Although the COVID-19 pandemic has increased the prevalence of cases with olfactory loss, other respiratory viru- ses can also cause this condition. We aimed to compare the prevalence of acute SARS-CoV-2 infection and other respiratory viru- ses in patients with sudden smell loss, and to assess the impact of SARS-CoV-2 viral load and co-infection on olfactory symptoms. Methods: Patients with sudden smell loss were recruited in a multicenter prospective cohort study in 15 hospitals in Brazil. Clinical questionnaire, Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test and nasopharyngeal swab to perform a PCR-based respiratory viral panel were collected at first visit (day 0) and 30 and 60 days after recruitment. Results: 188 of 213 patients presented positive test result for SARS-CoV-2, among which 65 were co-infected with other respira- tory viruses (e.g., rhinovirus, enterovirus, and parainfluenza). 25 had negative test results for SARS-CoV-2. Patients in both SARS- CoV-2 and non-SARS-CoV-2 groups had objective anosmia (<2 points according to the psychophysical olfactory CCCRC) at day 0, with no significant difference between them. Both groups had significant smell scores improvement after 30 and 60 days, with no difference between them. Co-infection with other respiratory viruses, and SARS-CoV-2 viral load did not impact olfactory scores. Conclusion: Patients with sudden smell loss associated with SARS-CoV-2 and other respiratory viruses had similar presentation, with most participants initiating with anosmia, and total or near total recovery after 60 days. SARS-CoV-2 viral load and co-infecti- ons with other respiratory viruses were not associated with poorer olfactory outcomes.
- 1 September 2023
- Published by Stichting Nase in Rhinology journal
- Vol. 62 (1) , 55-62
Smell loss associated with SARS-CoV-2 is not clinically different from other viruses: a multicenter cohort study
Background: Although the COVID-19 pandemic has increased the prevalence of cases with olfactory loss, other respiratory viru- ses can also cause this condition. We aimed to compare the prevalence of acute SARS-CoV-2 infection and other respiratory viru- ses in patients with sudden smell loss, and to assess the impact of SARS-CoV-2 viral load and co-infection on olfactory symptoms. Methods: Patients with sudden smell loss were recruited in a multicenter prospective cohort study in 15 hospitals in Brazil. Clinical questionnaire, Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test and nasopharyngeal swab to perform a PCR-based respiratory viral panel were collected at first visit (day 0) and 30 and 60 days after recruitment. Results: 188 of 213 patients presented positive test result for SARS-CoV-2, among which 65 were co-infected with other respira- tory viruses (e.g., rhinovirus, enterovirus, and parainfluenza). 25 had negative test results for SARS-CoV-2. Patients in both SARS- CoV-2 and non-SARS-CoV-2 groups had objective anosmia (<2 points according to the psychophysical olfactory CCCRC) at day 0, with no significant difference between them. Both groups had significant smell scores improvement after 30 and 60 days, with no difference between them. Co-infection with other respiratory viruses, and SARS-CoV-2 viral load did not impact olfactory scores. Conclusion: Patients with sudden smell loss associated with SARS-CoV-2 and other respiratory viruses had similar presentation, with most participants initiating with anosmia, and total or near total recovery after 60 days. SARS-CoV-2 viral load and co-infecti- ons with other respiratory viruses were not associated with poorer olfactory outcomes.
- Open Access
- 25 August 2023
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 89 (5) , 101307
Reliability of nasofibroscopy for the evaluation of adenoid hypertrophy and its correlation with clinical symptoms
- 25 August 2023
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 89 (5) , 101307
Open AccessReliability of nasofibroscopy for the evaluation of adenoid hypertrophy and its correlation with clinical symptoms
- Open Access
- 20 October 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88, 15
Comparative magnetic resonance analysis of olfactory bulb of individuals with post-COVID anosmia 19
- 20 October 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88, 15
Open AccessComparative magnetic resonance analysis of olfactory bulb of individuals with post-COVID anosmia 19
- 1 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 88 (3) , 471-480
Diretriz para o uso dos imunobiológicos em rinossinusite crônica com pólipo nasal (RSCcPN) no Brasil
- 1 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 88 (3) , 471-480
Diretriz para o uso dos imunobiológicos em rinossinusite crônica com pólipo nasal (RSCcPN) no Brasil
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 87 (4) , 377-378
Monitoramento de casos de anosmia pode ajudar a controlar a pandemia de Covid‐19
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 87 (4) , 377-378
Monitoramento de casos de anosmia pode ajudar a controlar a pandemia de Covid‐19
- Open Access
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (4) , 377-378
Monitoring of cases of anosmia may help control the COVID-19 pandemic
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (4) , 377-378
Open AccessMonitoring of cases of anosmia may help control the COVID-19 pandemic
- Open Access
- 3 April 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (3) , 471-480
Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
- 3 April 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (3) , 471-480
Open AccessGuideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
- Open Access
- 25 February 2019
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 17 (2) , eAO4423
Water protection in patients with tympanostomy tubes in tympanic membrane: a randomized clinical trial
To analyze the incidence of otorrhea in the postoperative period of patients submitted to tympanotomy to place ventilation tube, and who did not protect the ear when exposed to water. Open, randomized-controlled trial. Eighty patients submitted to unilateral or bilateral ear grommet tympanostomy were included and divided into two groups: Auricular Protection and Non-Protection to water during bathing and activities in water. In the first postoperative month, the Non-Protection Group presented a significant increase in the number of patients with otorrhea and in the incidence. Four patients of the Protection Group (11%) presented at least one episode of otorrhea in this period, representing an incidence of 0.11 (standard deviation ±0.32) episode/month, whereas in the Non-Protection Group there were 12 episodes (33%; p=0.045) and incidence of 0.33 (±0.48; p=0.02). Between the 2nd and the 13th postoperative months, there was no difference between groups. Seven patients in the Protection Group (20%) had at least one episode of otorrhea, representing an incidence of 0.04 (±0.09) episodes/month, while in the Non-Protection Group there were seven episodes (22%; p=0.8) and incidence of 0.05 (±0.1; p=0.8). Patients who underwent ear protection when exposed to water had a lower incidence of otorrhea in the first postoperative month than those who did not undergo protection. From the second month, there was no difference between groups.
- 25 February 2019
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 17 (2) , eAO4423
Open AccessWater protection in patients with tympanostomy tubes in tympanic membrane: a randomized clinical trial
To analyze the incidence of otorrhea in the postoperative period of patients submitted to tympanotomy to place ventilation tube, and who did not protect the ear when exposed to water. Open, randomized-controlled trial. Eighty patients submitted to unilateral or bilateral ear grommet tympanostomy were included and divided into two groups: Auricular Protection and Non-Protection to water during bathing and activities in water. In the first postoperative month, the Non-Protection Group presented a significant increase in the number of patients with otorrhea and in the incidence. Four patients of the Protection Group (11%) presented at least one episode of otorrhea in this period, representing an incidence of 0.11 (standard deviation ±0.32) episode/month, whereas in the Non-Protection Group there were 12 episodes (33%; p=0.045) and incidence of 0.33 (±0.48; p=0.02). Between the 2nd and the 13th postoperative months, there was no difference between groups. Seven patients in the Protection Group (20%) had at least one episode of otorrhea, representing an incidence of 0.04 (±0.09) episodes/month, while in the Non-Protection Group there were seven episodes (22%; p=0.8) and incidence of 0.05 (±0.1; p=0.8). Patients who underwent ear protection when exposed to water had a lower incidence of otorrhea in the first postoperative month than those who did not undergo protection. From the second month, there was no difference between groups.
- Open Access
- 1 September 2018
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 4 (3) , 169-174
P‐glycoprotein and chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a heterogeneous definition that includes different disease states that usually are associated with abnormal inflammatory responses. Besides being prevalent, the mechanisms involved in its pathogenesis are not clear and there are few therapeutic options with tolerable side effects. P‐glycoprotein (P‐gp) is an efflux pump responsible of extruding xenobiotics and cellular metabolites from multiple cell types. It has been widely studied in the cancer field, due to its ability to confer resistance to chemotherapy. It also promotes Type 2 helper T‐cell polarizing cytokine secretion in CRS and may represent a potential target to differentiate subtypes of CRS and personalize treatment. This state‐of‐the‐art review explores current knowledge on the participation of P‐gp in the pathogenesis of CRS, the P‐gp inhibition as a novel targeted therapeutic strategy and the exosomal P‐gp test, a non‐invasive biomarker that can represent an important advance in the field of rhinology.
- 1 September 2018
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 4 (3) , 169-174
Open AccessP‐glycoprotein and chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a heterogeneous definition that includes different disease states that usually are associated with abnormal inflammatory responses. Besides being prevalent, the mechanisms involved in its pathogenesis are not clear and there are few therapeutic options with tolerable side effects. P‐glycoprotein (P‐gp) is an efflux pump responsible of extruding xenobiotics and cellular metabolites from multiple cell types. It has been widely studied in the cancer field, due to its ability to confer resistance to chemotherapy. It also promotes Type 2 helper T‐cell polarizing cytokine secretion in CRS and may represent a potential target to differentiate subtypes of CRS and personalize treatment. This state‐of‐the‐art review explores current knowledge on the participation of P‐gp in the pathogenesis of CRS, the P‐gp inhibition as a novel targeted therapeutic strategy and the exosomal P‐gp test, a non‐invasive biomarker that can represent an important advance in the field of rhinology.